One-year adherence to clinic visits after highly active antiretroviral therapy: A predictor of clinical progress in HIV patients

Journal of Internal Medicine

Volumn 261, Issue 3, 2007, Pages 268-275

  Park, W B ^a   Choe, P G ^a   Kim, S H ^a   Jo, J H ^a   Bang, J H ^a   Kim, H B ^a   Kim, N J ^a   Oh, M ^a   Choe, K W ^a  

^a Seoul National University   (South Korea)

Author keywords

AIDS; Compliance; Highly active antiretroviral therapy; HIV; Outcome

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS LOAD;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33846967398     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2006.01762.x     Document Type: Article

References (22)

1. Detels R, Munoz A, McFarlane G et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998; 280: 1497-503.
2. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353: 863-8.
3. Hogg RS, Heath K, Bangsberg D et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16: 1051-8.
4. -1. Ann Intern Med 2003; 139: 810-6.
5. Bangsberg DR, Perry S, Charlebois ED et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15: 1181-3.
6. Mocroft A, Youle M, Moore A et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15: 185-94.
7. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6: 592-9.
8. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care 1997; 8: 43-54.
9. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-7.
10. Rastegar DA, Fingerhood MI, Jasinski DR. Highly active antiretroviral therapy outcomes in a primary care clinic. AIDS Care 2003; 15: 231-7.
11. Center for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1-19.
12. Levine AM, Richardson JL, Marks G et al. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469-76.
13. Wood PR, Casey R, Kolski GB, McCormick MC. Compliance with oral theophylline therapy in asthmatic children. Ann Allergy 1985; 54: 400-4.
14. Greub G, Cozzi-Lepri A, Ledergerber B et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16: 1967-9.
15. Havlir DV, Bassett R, Levitan D et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286: 171-9.
16. 3. J Infect Dis 2005; 192: 950-7.
17. Kitahata MM, Reed SD, Dillingham PW et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS 2004; 15: 803-10.
18. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 447-54.
19. Mocroft A, Ledergerber B, Viard JP et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis 2004; 190: 1947-56.
20. d'Arminio MA, Testa L, Adorni F et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998; 12: 1631-7.
21. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334: 701-6.
22. Macharia WM, Leon G, Rowe BH, Stephenson BJ, Haynes RB. An overview of interventions to improve compliance with appointment keeping for medical services. JAMA 1992; 267: 1813-7.